Cambridge Nutritional Sciences plc (AIM: CNSL)
London
· Delayed Price · Currency is GBP · Price in GBX 3.515
-0.185 (-4.99%)
Jan 22, 2025, 8:45 AM GMT+1
AIM: CNSL Revenue
Cambridge Nutritional Sciences had revenue of 4.13M GBP in the half year ending September 30, 2024, with 20.38% growth. This brings the company's revenue in the last twelve months to 8.97M, down -0.80% year-over-year. In the fiscal year ending March 31, 2024, Cambridge Nutritional Sciences had annual revenue of 9.77M with 29.53% growth.
Revenue (ttm)
8.97M
Revenue Growth
-0.80%
P/S Ratio
0.98
Revenue / Employee
95.47K
Employees
94
Market Cap
8.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 9.77M | 2.23M | 29.53% |
| Mar 31, 2023 | 7.55M | -993.00K | -11.63% |
| Mar 31, 2022 | 8.54M | 1.72M | 25.28% |
| Mar 31, 2021 | 6.82M | -3.00M | -30.58% |
| Mar 31, 2020 | 9.82M | 1.06M | 12.13% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |